Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia
Dasatinib (DAS) has been licensed for the frontline treatment in chronic myeloid leukemia (CML). However, very few data are available regarding its efficacy and toxicity in elderly patients with CML outside clinical trials. To address this issue, we set out a “real-life” cohort of 65 chronic phase C...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2016-09-01
|
| Series: | Neoplasia: An International Journal for Oncology Research |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1476558616300471 |
| _version_ | 1818265574518554624 |
|---|---|
| author | Roberto Latagliata Fabio Stagno Mario Annunziata Elisabetta Abruzzese Alessandra Iurlo Attilio Guarini Carmen Fava Antonella Gozzini Massimiliano Bonifacio Federica Sorà Sabrina Leonetti Crescenzi Monica Bocchia Monica Crugnola Fausto Castagnetti Isabella Capodanno Sara Galimberti Costanzo Feo Raffaele Porrini Patrizia Pregno Manuela Rizzo Agostino Antolino Endri Mauro Nicola Sgherza Luigiana Luciano Mario Tiribelli Antonella Russo Rossi Malgorzata Trawinska Paolo Vigneri Massimo Breccia Gianantonio Rosti Giuliana Alimena |
| author_facet | Roberto Latagliata Fabio Stagno Mario Annunziata Elisabetta Abruzzese Alessandra Iurlo Attilio Guarini Carmen Fava Antonella Gozzini Massimiliano Bonifacio Federica Sorà Sabrina Leonetti Crescenzi Monica Bocchia Monica Crugnola Fausto Castagnetti Isabella Capodanno Sara Galimberti Costanzo Feo Raffaele Porrini Patrizia Pregno Manuela Rizzo Agostino Antolino Endri Mauro Nicola Sgherza Luigiana Luciano Mario Tiribelli Antonella Russo Rossi Malgorzata Trawinska Paolo Vigneri Massimo Breccia Gianantonio Rosti Giuliana Alimena |
| author_sort | Roberto Latagliata |
| collection | DOAJ |
| description | Dasatinib (DAS) has been licensed for the frontline treatment in chronic myeloid leukemia (CML). However, very few data are available regarding its efficacy and toxicity in elderly patients with CML outside clinical trials. To address this issue, we set out a “real-life” cohort of 65 chronic phase CML patients older than 65 years (median age 75.1 years) treated frontline with DAS in 26 Italian centers from June 2012 to June 2015, focusing our attention on toxicity and efficacy data. One third of patients (20/65: 30.7%) had 3 or more comorbidities and required concomitant therapies; according to Sokal classification, 3 patients (4.6%) were low risk, 39 (60.0%) intermediate risk, and 20 (30.8%) high risk, whereas 3 (4.6%) were not classifiable. DAS starting dose was 100 mg once a day in 54 patients (83.0%), whereas 11 patients (17.0%) received less than 100 mg/day. Grade 3/4 hematologic and extrahematologic toxicities were reported in 8 (12.3%) and 12 (18.5%) patients, respectively. Overall, 10 patients (15.4%) permanently discontinued DAS because of toxicities. Pleural effusions (all WHO grades) occurred in 12 patients (18.5%) and in 5 of them occurred during the first 3 months. DAS treatment induced in 60/65 patients (92.3%) a complete cytogenetic response and in 50/65 (76.9%) also a major molecular response. These findings show that DAS might play an important role in the frontline treatment of CML patients >65 years old, proving efficacy and having a favorable safety profile also in elderly subjects with comorbidities. |
| first_indexed | 2024-12-12T19:52:58Z |
| format | Article |
| id | doaj.art-cf326cb4083d49d69854ac476b662cf8 |
| institution | Directory Open Access Journal |
| issn | 1476-5586 1522-8002 |
| language | English |
| last_indexed | 2024-12-12T19:52:58Z |
| publishDate | 2016-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Neoplasia: An International Journal for Oncology Research |
| spelling | doaj.art-cf326cb4083d49d69854ac476b662cf82022-12-22T00:13:57ZengElsevierNeoplasia: An International Journal for Oncology Research1476-55861522-80022016-09-0118953654010.1016/j.neo.2016.07.005Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid LeukemiaRoberto Latagliata0Fabio Stagno1Mario Annunziata2Elisabetta Abruzzese3Alessandra Iurlo4Attilio Guarini5Carmen Fava6Antonella Gozzini7Massimiliano Bonifacio8Federica Sorà9Sabrina Leonetti Crescenzi10Monica Bocchia11Monica Crugnola12Fausto Castagnetti13Isabella Capodanno14Sara Galimberti15Costanzo Feo16Raffaele Porrini17Patrizia Pregno18Manuela Rizzo19Agostino Antolino20Endri Mauro21Nicola Sgherza22Luigiana Luciano23Mario Tiribelli24Antonella Russo Rossi25Malgorzata Trawinska26Paolo Vigneri27Massimo Breccia28Gianantonio Rosti29Giuliana Alimena30Department of Cellular Biotechnologies and Hematology, “Sapienza” University, RomeChair and Division of Hematology, Ferrarotto Hospital-AOU Policlinic V. Emanuele, CataniaHematology with Transplantation, Cardarelli Hospitali, NeaplesHematology, Sant'Eugenio Hospital, RomeUOC Onco-hematology, IRCCS Ca’ Granda Foundation-Ospedale Maggiore Policlinico, MilanHematology Unit, Cancer Institute “Giovanni Paolo II”, BariDepartment of Clinical and Biological Sciences, University of Turin, San Luigi Gonzaga Hospital, OrbassanoHematology, University of FlorenceDepartment of Medicine, Section of Hematology, University of VeronaHematology, Catholic University of Sacred Heart of RomeHematology, Sandro Pertini Hospital, RomeDivision of Hematology, University of SienaHematology, University of ParmaDepartment of Hematology and Oncology “L. and A. Seràgnoli,”, S. Orsola-Malpighi University Hospital, BolognaHematology, Arcispedale Santa Maria Nuova, Reggio EmiliaDepartment of Clinical and Experimental Medicine-Hematology, University of PisaHematology, Rummo Hospital, BeneventoHematology, Sant'Andrea Hospital, University “Sapienza” RomeHematology, San Giovanni Battista Hospital and University, TurinHematology, University “Tor Vergata” of RomeHematology, ASP7, RagusaDepartment of Internal Medicine, General Hospital, PordenoneHematology, IRCCS, “Casa Sollievo della Sofferenza”, San Giovanni RotondoHematology, University “Federico II” of NeaplesHematology, Hospital-University of UdineHematology with Transplant, University of BariHematology, Sant'Eugenio Hospital, RomeMedical Oncology, AOU Policlinic V. Emanuele, University of CataniaDepartment of Cellular Biotechnologies and Hematology, “Sapienza” University, RomeDepartment of Hematology and Oncology “L. and A. Seràgnoli,”, S. Orsola-Malpighi University Hospital, BolognaDepartment of Cellular Biotechnologies and Hematology, “Sapienza” University, RomeDasatinib (DAS) has been licensed for the frontline treatment in chronic myeloid leukemia (CML). However, very few data are available regarding its efficacy and toxicity in elderly patients with CML outside clinical trials. To address this issue, we set out a “real-life” cohort of 65 chronic phase CML patients older than 65 years (median age 75.1 years) treated frontline with DAS in 26 Italian centers from June 2012 to June 2015, focusing our attention on toxicity and efficacy data. One third of patients (20/65: 30.7%) had 3 or more comorbidities and required concomitant therapies; according to Sokal classification, 3 patients (4.6%) were low risk, 39 (60.0%) intermediate risk, and 20 (30.8%) high risk, whereas 3 (4.6%) were not classifiable. DAS starting dose was 100 mg once a day in 54 patients (83.0%), whereas 11 patients (17.0%) received less than 100 mg/day. Grade 3/4 hematologic and extrahematologic toxicities were reported in 8 (12.3%) and 12 (18.5%) patients, respectively. Overall, 10 patients (15.4%) permanently discontinued DAS because of toxicities. Pleural effusions (all WHO grades) occurred in 12 patients (18.5%) and in 5 of them occurred during the first 3 months. DAS treatment induced in 60/65 patients (92.3%) a complete cytogenetic response and in 50/65 (76.9%) also a major molecular response. These findings show that DAS might play an important role in the frontline treatment of CML patients >65 years old, proving efficacy and having a favorable safety profile also in elderly subjects with comorbidities.http://www.sciencedirect.com/science/article/pii/S1476558616300471 |
| spellingShingle | Roberto Latagliata Fabio Stagno Mario Annunziata Elisabetta Abruzzese Alessandra Iurlo Attilio Guarini Carmen Fava Antonella Gozzini Massimiliano Bonifacio Federica Sorà Sabrina Leonetti Crescenzi Monica Bocchia Monica Crugnola Fausto Castagnetti Isabella Capodanno Sara Galimberti Costanzo Feo Raffaele Porrini Patrizia Pregno Manuela Rizzo Agostino Antolino Endri Mauro Nicola Sgherza Luigiana Luciano Mario Tiribelli Antonella Russo Rossi Malgorzata Trawinska Paolo Vigneri Massimo Breccia Gianantonio Rosti Giuliana Alimena Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia Neoplasia: An International Journal for Oncology Research |
| title | Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia |
| title_full | Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia |
| title_fullStr | Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia |
| title_full_unstemmed | Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia |
| title_short | Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia |
| title_sort | frontline dasatinib treatment in a real life cohort of patients older than 65 years with chronic myeloid leukemia |
| url | http://www.sciencedirect.com/science/article/pii/S1476558616300471 |
| work_keys_str_mv | AT robertolatagliata frontlinedasatinibtreatmentinareallifecohortofpatientsolderthan65yearswithchronicmyeloidleukemia AT fabiostagno frontlinedasatinibtreatmentinareallifecohortofpatientsolderthan65yearswithchronicmyeloidleukemia AT marioannunziata frontlinedasatinibtreatmentinareallifecohortofpatientsolderthan65yearswithchronicmyeloidleukemia AT elisabettaabruzzese frontlinedasatinibtreatmentinareallifecohortofpatientsolderthan65yearswithchronicmyeloidleukemia AT alessandraiurlo frontlinedasatinibtreatmentinareallifecohortofpatientsolderthan65yearswithchronicmyeloidleukemia AT attilioguarini frontlinedasatinibtreatmentinareallifecohortofpatientsolderthan65yearswithchronicmyeloidleukemia AT carmenfava frontlinedasatinibtreatmentinareallifecohortofpatientsolderthan65yearswithchronicmyeloidleukemia AT antonellagozzini frontlinedasatinibtreatmentinareallifecohortofpatientsolderthan65yearswithchronicmyeloidleukemia AT massimilianobonifacio frontlinedasatinibtreatmentinareallifecohortofpatientsolderthan65yearswithchronicmyeloidleukemia AT federicasora frontlinedasatinibtreatmentinareallifecohortofpatientsolderthan65yearswithchronicmyeloidleukemia AT sabrinaleonetticrescenzi frontlinedasatinibtreatmentinareallifecohortofpatientsolderthan65yearswithchronicmyeloidleukemia AT monicabocchia frontlinedasatinibtreatmentinareallifecohortofpatientsolderthan65yearswithchronicmyeloidleukemia AT monicacrugnola frontlinedasatinibtreatmentinareallifecohortofpatientsolderthan65yearswithchronicmyeloidleukemia AT faustocastagnetti frontlinedasatinibtreatmentinareallifecohortofpatientsolderthan65yearswithchronicmyeloidleukemia AT isabellacapodanno frontlinedasatinibtreatmentinareallifecohortofpatientsolderthan65yearswithchronicmyeloidleukemia AT saragalimberti frontlinedasatinibtreatmentinareallifecohortofpatientsolderthan65yearswithchronicmyeloidleukemia AT costanzofeo frontlinedasatinibtreatmentinareallifecohortofpatientsolderthan65yearswithchronicmyeloidleukemia AT raffaeleporrini frontlinedasatinibtreatmentinareallifecohortofpatientsolderthan65yearswithchronicmyeloidleukemia AT patriziapregno frontlinedasatinibtreatmentinareallifecohortofpatientsolderthan65yearswithchronicmyeloidleukemia AT manuelarizzo frontlinedasatinibtreatmentinareallifecohortofpatientsolderthan65yearswithchronicmyeloidleukemia AT agostinoantolino frontlinedasatinibtreatmentinareallifecohortofpatientsolderthan65yearswithchronicmyeloidleukemia AT endrimauro frontlinedasatinibtreatmentinareallifecohortofpatientsolderthan65yearswithchronicmyeloidleukemia AT nicolasgherza frontlinedasatinibtreatmentinareallifecohortofpatientsolderthan65yearswithchronicmyeloidleukemia AT luigianaluciano frontlinedasatinibtreatmentinareallifecohortofpatientsolderthan65yearswithchronicmyeloidleukemia AT mariotiribelli frontlinedasatinibtreatmentinareallifecohortofpatientsolderthan65yearswithchronicmyeloidleukemia AT antonellarussorossi frontlinedasatinibtreatmentinareallifecohortofpatientsolderthan65yearswithchronicmyeloidleukemia AT malgorzatatrawinska frontlinedasatinibtreatmentinareallifecohortofpatientsolderthan65yearswithchronicmyeloidleukemia AT paolovigneri frontlinedasatinibtreatmentinareallifecohortofpatientsolderthan65yearswithchronicmyeloidleukemia AT massimobreccia frontlinedasatinibtreatmentinareallifecohortofpatientsolderthan65yearswithchronicmyeloidleukemia AT gianantoniorosti frontlinedasatinibtreatmentinareallifecohortofpatientsolderthan65yearswithchronicmyeloidleukemia AT giulianaalimena frontlinedasatinibtreatmentinareallifecohortofpatientsolderthan65yearswithchronicmyeloidleukemia |